Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612.
Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL 33620; and.
J Immunol. 2020 Nov 15;205(10):2893-2904. doi: 10.4049/jimmunol.2000759. Epub 2020 Oct 5.
The activation of 41BB costimulatory signals by agonistic Abs enhances the expansion and function of tumor-infiltrating lymphocytes (TILs) for treating cancer patients with adoptive cell therapy. However, the impact of 41BB agonism is not limited to enhancing the activity of T cells, and the mechanism by which additional activation of this costimulatory axis in tumor-associated myeloid cells is poorly understood. In this study, we describe that the intratumoral administration of 41BB agonistic Abs led to increases in CD8 T cell infiltration followed by tumor regression in murine models. We found that granulocytes and monocytes rapidly replaced macrophages and dendritic cells in tumors following administration of anti-41BB Abs. Overall, myeloid cells from anti-41BB-treated tumors had an improved capacity to stimulate T cells in comparison with control-treated tumors. In human coculture systems, we demonstrated that the agonism of the 41BB-41BBL axis enhanced costimulatory signals and effector functions among APC and autologous TILs. Overall, these findings suggest that the effect of 41BB agonistic Abs are supported by additional costimulatory signals from tumor-associated myeloid cells,v leading to enhanced TIL expansion and function.
激动性抗体激活 41BB 共刺激信号可增强肿瘤浸润淋巴细胞(TIL)的扩增和功能,从而用过继细胞疗法治疗癌症患者。然而,41BB 激动作用的影响不仅限于增强 T 细胞的活性,并且在肿瘤相关髓样细胞中这条共刺激轴的额外激活的机制尚未完全阐明。在这项研究中,我们描述了在肿瘤内给予 41BB 激动性抗体可导致 CD8 T 细胞浸润增加,随后在小鼠模型中肿瘤消退。我们发现,在用抗 41BB 抗体治疗后,粒细胞和单核细胞迅速取代了肿瘤中的巨噬细胞和树突状细胞。总体而言,与对照治疗的肿瘤相比,来自抗 41BB 治疗的肿瘤的髓样细胞具有增强的刺激 T 细胞的能力。在人类共培养系统中,我们证明了 41BB-41BBL 轴的激动作用增强了 APC 和自体 TIL 之间的共刺激信号和效应功能。总体而言,这些发现表明,41BB 激动性抗体的作用得到了来自肿瘤相关髓样细胞的其他共刺激信号的支持,从而增强了 TIL 的扩增和功能。